.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its top biopharma pick for 2025 as well as measured one more nine labels in the area as obese. The expenditure bank said in a note that it continues to feel “diabesity is readied to come to be.